Drug Pipeline News

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.

Evinacumab phase 3 results show a 48% LDL-C reduction in children with homozygous familial hypercholesterolemia.

A look at what the Contemporary Pediatrics® team covered this week.

Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.

Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editor-in-chief Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, discusses how to help parents who are worried or nervous about the delay in the expansion of the Pfizer/BioNTech vaccine to children aged 6 months to younger than 4 years.

The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years.

The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.

Abigail Donovan, MD, discusses what brexpiprazole can do for treating schizophrenia in older children.